title: Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy.
abstract: Rheumatoid arthritis is a chronic, systemic, autoimmune, and inflammatory disorder that affects the synovial lining of the joints. We describe the beneficial effects of the pituitary adenylate cyclase-activating polypeptide (PACAP) in the collagen-induced arthritis experimental murine model being proposed as a novel therapeutic approach in the treatment of rheumatoid arthritis. PACAP greatly decreases arthritis frequency and severity in the studied mice by improving clinical symptoms, ameliorating joint damage, and blocking both the inflammatory and autoimmune mediators which are the main keys of the pathogenesis of this disease. With this study, PACAP emerges as a promising candidate for the treatment of a pathology with a high world incidence but currently no effective treatment.
authors.affiliation: Department of Cell Biology, Faculty of Biology, Complutense University, Madrid, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Abad
authors.forename: C
authors.initials: C
authors.lastname: Martinez
authors.forename: J
authors.initials: J
authors.lastname: Leceta
authors.forename: R P
authors.initials: RP
authors.lastname: Gomariz
authors.forename: M
authors.initials: M
authors.lastname: Delgado
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D019264:Adoptive Transfer; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000209:etiology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002417:Cattle; D002478:Cells, Cultured; D003094:Collagen / Q000276:immunology / Q000633:toxicity; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004790:Enzyme Induction / Q000187:drug effects; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000235:genetics; D018655:Lymphocyte Count; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis / Q000235:genetics; D051379:Mice; D008811:Mice, Inbred DBA; D009479:Neuropeptides / Q000494:pharmacology / Q000627:therapeutic use*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D013583:Synovial Membrane / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000637:transplantation; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism
chemical_list: C495402:Adcyap1 protein, mouse; D000276:Adjuvants, Immunologic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D007074:Immunoglobulin G; D009479:Neuropeptides; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D003094:Collagen; D020778:Matrix Metalloproteinase 2